Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside

By Yahoo! Finance | Oct 17, 2024 at 02:45 PM EST

HC Wainwright has initiated coverage on Alumis Inc., a biopharmaceutical company developing oral therapies for immune-mediated diseases. Their lead drug candidate, ESK-001, shows promise in Phase 3 trials for plaque psoriasis and Phase 2 trials for lupus.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.